Clinical trials
Immunoglobulin Light-chain Amyloidosis trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 3 |
| GlaxoSmithKline | 3 |
| Prothena Biosciences Ltd. | 3 |
| European Myeloma Network B.V. | 1 |
| Lantheus Germany GmbH | 1 |
| Oncopeptides AB | 1 |
| Sanofi | 1 |
| Stichting European Myeloma Network | 1 |
| UK Kidney Association | 1 |
| University College, London | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunoglobulin Light-chain Amyloidosis | 17 |
| Amyloidosis | 6 |
| Paraproteinemias | 3 |
| Multiple Myeloma | 2 |
| Alzheimer Disease | 1 |
| Amyloid Neuropathies, Familial | 1 |
| Anxiety Disorders | 1 |
| Atypical Hemolytic Uremic Syndrome | 1 |
| Bartter Syndrome | 1 |
| Blast Crisis | 1 |
Trials
Showing 26 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.